The Phenotypical Characterization of Dual-Nature Hybrid Cells in Uveal Melanoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Sep 28

PMID 39335202

Authors

Emily Marcotte

Alicia Goyeneche

Mohamed Abdouh

Julia Valdemarin Burnier

Miguel Noel Burnier Jr

Affiliations

Soon will be listed here.

Abstract

Background: Metastasis, occurring years after primary diagnosis, represents a poor prognosis in uveal melanoma (UM)-affected individuals. The nature of cells involved in this process is under debate. Circulating hybrid cells that have combined tumor and immune cell features found in blood were predictive of metastasis and may correspond to dual-nature cells (DNC) in the primary tumor. Herein, we sought to determine the presence of DNCs in primary UM tumors, the cell types involved in their genesis, and their ability to be formed in vitro.

Methods: UM lesions (n = 38) were immunolabeled with HMB45 in combination with immune-cell-specific antibodies. In parallel, we co-cultured UM cells and peripheral blood mononuclear cells (PBMCs) to analyze DNC formation.

Results: HMB45/CD45 DNCs were present in 90% (26/29) of the tumors, HMB45/CD8 DNCs were present in 93% (26/28), and HMB45/CD68 DNCs were present in 71% (17/24). DNCs formed with CD8 and CD68 cells were positively correlated to the infiltration of their respective immune cells. Notably, UM cells were prone to hybridize with PBMCs in vitro.

Conclusions: This phenotypical characterization of DNCs in UM demonstrates that CD8 T-cells and macrophages are capable of DNC formation, and they are important for better understanding metastatic dissemination, thus paving the path towards novel therapeutic avenues.

References

Silva-Rodriguez P, Fernandez-Diaz D, Bande M, Pardo M, Loidi L, Blanco-Teijeiro M . and Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma. Cancers (Basel). 2022; 14(13). PMC: 9264989. DOI: 10.3390/cancers14133066. View

Tuthill R, Unger J, Liu P, Flaherty L, Sondak V . Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002; 118(4):504-11. DOI: 10.1309/WBF7-N8KH-71KT-RVQ9. View

Finger P, Kurli M, Reddy S, Tena L, Pavlick A . Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol. 2005; 89(10):1270-4. PMC: 1772897. DOI: 10.1136/bjo.2005.069823. View

Whelchel J, Farah S, McLean I, Burnier M . Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 1993; 34(8):2603-6. View

Vajdic C, Kricker A, Giblin M, McKenzie J, Aitken J, Giles G . Incidence of ocular melanoma in Australia from 1990 to 1998. Int J Cancer. 2003; 105(1):117-22. DOI: 10.1002/ijc.11057. View

Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson R, Peer J . The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993; 100(9):1389-98. DOI: 10.1016/s0161-6420(93)31470-3. View

JENSEN O . Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943--1952. Acta Ophthalmol (Copenh). 1982; 60(2):161-82. DOI: 10.1111/j.1755-3768.1982.tb08371.x. View

Yu F, Luo J, Mo J, Liu G, Kim Y, Meng Z . Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014; 25(6):822-30. PMC: 4075337. DOI: 10.1016/j.ccr.2014.04.017. View

Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E . Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114(12):2309-15. DOI: 10.1016/j.ophtha.2007.01.032. View

10.

Anderson A, Conley P, Klocke C, Sengupta S, Pang A, Farley H . Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma. Biomark Res. 2024; 12(1):67. PMC: 11264923. DOI: 10.1186/s40364-024-00609-6. View

11.

Li H, Li Q, Dang K, Ma S, Cotton J, Yang S . YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression. Cell Rep. 2019; 29(10):3200-3211.e4. PMC: 7871510. DOI: 10.1016/j.celrep.2019.03.021. View

12.

Jin E, Burnier J . Liquid Biopsy in Uveal Melanoma: Are We There Yet?. Ocul Oncol Pathol. 2021; 7(1):1-16. PMC: 7989728. DOI: 10.1159/000508613. View

13.

Logan P, Fernandes B, Di Cesare S, Marshall J, Maloney S, Burnier Jr M . Single-cell tumor dormancy model of uveal melanoma. Clin Exp Metastasis. 2008; 25(5):509-16. DOI: 10.1007/s10585-008-9158-2. View

14.

Zhou R, Caspi R . Ocular immune privilege. F1000 Biol Rep. 2010; 2. PMC: 2948372. DOI: 10.3410/B2-3. View

15.

Dietz M, Sutton T, Walker B, Gast C, Zarour L, Sengupta S . Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. Sci Rep. 2021; 11(1):13630. PMC: 8249418. DOI: 10.1038/s41598-021-93053-7. View

16.

Makitie T, Summanen P, Tarkkanen A, Kivela T . Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42(7):1414-21. View

17.

Diener-West M, Reynolds S, Agugliaro D, Caldwell R, Cumming K, Earle J . Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005; 123(12):1639-43. DOI: 10.1001/archopht.123.12.1639. View

18.

Mougiakakos D, Johansson C, Trocme E, All-Ericsson C, Economou M, Larsson O . Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer. 2010; 116(9):2224-33. DOI: 10.1002/cncr.24999. View

19.

McLean I, FOSTER W, ZIMMERMAN L, Gamel J . Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983; 96(4):502-9. DOI: 10.1016/s0002-9394(14)77914-0. View

20.

Shields C, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally D . Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127(8):989-98. DOI: 10.1001/archophthalmol.2009.208. View